Dawn of a new era: ctDNA-based biomarker detection for cancer diagnosis, response monitoring, and minimal residual disease

Dr. Chu has more than 20 years of biomarker research and CDx development experience in the pharmaceutical industry. Before joining Cogent Biosciences, he headed the clinical biomarker team at Luzsana Biotech (Hengrui USA) and oversaw the strategies on the CDx development path for oncology and non-oncology pipelines. He joined Sanofi in 2000 and led research teams in proteomics, antibody drug discovery, biomarker, and clinical bioanalysis for over twenty years.

Dr. Zhihong (Joe) Zhang has served as Burning Rock's chief technology officer since March 2016. He obtained a bachelor's and master's degree in biochemistry and molecular biology from Fudan University in 1997 and 2000 and a Ph.D. in molecular genetics and microbiology from Duke University in 2005. After receiving his Ph.D., Joe landed a position in the genome science department of Howard Hughes Institute of Medicine at the University of Washington as a Senior Researcher. Before joining Burning Rock, Joe was a staff scientist of Illumina, Inc., and experienced in leading cross-functional project teams including marketing, operation, customer solution, bioinformatics, and software for several successfully launched products, including Infinium Omni 2.5M-8, 5M-4 gene sub-typing chip, TruSeq Dual Index Sequencing, TruSeq DNA Ht, TruSeq Stranded RNA HT, TruSeq Exome, TruSeq Synthetic Long-Read DNA.